Glazer Capital LLC Takes $284,000 Position in Nexvet Biopharma plc (NASDAQ:NVET)

Glazer Capital LLC purchased a new stake in Nexvet Biopharma plc (NASDAQ:NVET) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 42,605 shares of the biopharmaceutical company’s stock, valued at approximately $284,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Kassirer Asset Management Corp bought a new position in shares of Nexvet Biopharma plc during the 2nd quarter worth approximately $803,000. S. Muoio & CO. LLC bought a new stake in shares of Nexvet Biopharma plc in the 2nd quarter valued at $387,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in shares of Nexvet Biopharma plc in the 2nd quarter valued at $476,000. Finally, Harvest Management LLC bought a new stake in shares of Nexvet Biopharma plc in the 2nd quarter valued at $335,000. 48.38% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/02/glazer-capital-llc-takes-284000-position-in-nexvet-biopharma-plc-nvet.html.

Shares of Nexvet Biopharma plc (NASDAQ NVET) remained flat at $6.72 on Monday. The company’s stock had a trading volume of 33,498 shares. Nexvet Biopharma plc has a 52 week low of $2.75 and a 52 week high of $6.72.

Nexvet Biopharma plc Company Profile

Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to

Other institutional investors and hedge funds have also modified their holdings of the company. Kassirer Asset Management Corp bought a new position in shares of Nexvet Biopharma plc during the 2nd quarter worth approximately $803,000. S. Muoio & CO. LLC bought a new stake in shares of Nexvet Biopharma plc in the 2nd quarter valued at $387,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in shares of Nexvet Biopharma plc in the 2nd quarter valued at $476,000. Finally, Harvest Management LLC bought a new stake in shares of Nexvet Biopharma plc in the 2nd quarter valued at $335,000. 48.38% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/02/glazer-capital-llc-takes-284000-position-in-nexvet-biopharma-plc-nvet.html.

Shares of Nexvet Biopharma plc (NASDAQ NVET) remained flat at $6.72 on Monday. The company’s stock had a trading volume of 33,498 shares. Nexvet Biopharma plc has a 52 week low of $2.75 and a 52 week high of $6.72.

Nexvet Biopharma plc Company Profile

Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity.

Institutional Ownership by Quarter for Nexvet Biopharma plc (NASDAQ:NVET)

Receive News & Ratings for Nexvet Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexvet Biopharma plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply